Biagio Ricciuti։ Discussion on the Evolving Landscape of KRAS- and RAS-Targeted Therapies at Hawaii Lung26
Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber Cancer Institute, shared on LinkedIn: “Thoughtful discussion today at Hawaii Lung26 with a stellar faculty on the evolving landscape of…
Read the full articleYou might also wanna read
Expert Panel Discussion on Personalized Decision-Making for HER2-Mutated NSCLC
Get the latest updates on HER2-mutated NSCLC.
mdsc.pe·1d agoDaraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM
Results of the earlier phase 1-2 study of 168 patients, published recently 🧪💊
Our response to the daraxonrasib clinical study and KRAS inhibitors
Our comment on daraxonrasib results and the promising group of therapies known as KRAS inhibitors. The post Our response to the daraxonrasib
Did ASCO 2026 Deliver on Its Biggest Pre-Meeting Predictions?
Early results showing significant improvements in OS and progression-free survival [PFS] vs standard chemotherapy suggest that direct RAS ta
STAT+: Roche drug sets new standard for KRAS-driven lung cancer
Biotech's bull market, Vertex's gene therapy expansion, and more news from The Readout
Lung Cancer Patients on Drug From China’s Akeso Lived Longer
Promising news announced #ASCO26 for patients with #lungcancer. Dr. Roy Herbst comments on ivonescimab, noting the initial study results fro
Comments
Sign in to join the conversation.
No comments yet. Be the first.